Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Clinical Oncology/Epidemiology
  • Published:

Clinical Oncology/Epidemiology

Drug acetylation in breast cancer

Abstract

The acetylator phenotype was determined in 100 patients with breast cancer and 100 control female subjects using isoniazid. The proportion of fast acetylators in the breast cancer patients (43%) was not significantly different from the control group (43%). We conclude that acetylator phenotype is unlikely to be an important determinant of the risk of developing breast cancer.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Webster, D., Flook, D., Jenkins, J. et al. Drug acetylation in breast cancer. Br J Cancer 60, 236–237 (1989). https://doi.org/10.1038/bjc.1989.260

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/bjc.1989.260

This article is cited by

Search

Quick links